Press & news
Matt Franklin, MBA, appointed as Biofidelity Non-Executive Director
Nov 17. 2022
Biofidelity has expanded its Board of Directors to include Matt Franklin, MBA, who will join as a Non-Executive Director.
Biofidelity announces presentation of new data on novel genomic technology at AMP 2022
Oct 28. 2022
ASPYRE simplifies & accelerates the detection of biomarkers in both DNA & RNA to facilitate selection of the most effective targeted cancer treatments
New data demonstrates novel genomic technology provides ultra-sensitive detection of gene fusions from RNA
Oct 18. 2022
Current sequencing methods miss gene fusions for many non-small cell lung cancer patients denying them access to targeted therapies.
Biomarkers RNA: what is ASPYRE technology?
Dec 1. 2022
Biofidelity’s Wendy Levin MD, MS, Chief Medical Officer, and Todd Kelley MD, Executive Director of Medical Affairs, were interviewed by OncologyTube.com about our recent publication in BMC Genomics.
Biofidelity raises $23m in oversubscribed Series A+ round
Feb 1. 2022
Biofidelity, a Cambridge and US pioneer in precision cancer diagnostics, has completed a significantly oversubscribed $23 million Series A+ round, led by Octopus Ventures and backed by SBI Investment Co. Ltd. and existing investors.
Biofidelity set to trigger diagnostics revolution in US
Jan 13. 2022
Cambridge Science Park company Biofidelity expects to launch ASPYRE-Lung, its first commercial diagnostic assay in the US in early 2022.